CD19 and acute lymphoblastic leukemia: The single-arm pilot study reported the security, and clinical efficiency of CD19 CAR T constructed with a replacement anti-CD19 chimeric antigen receptor (HI19α-4–1BB-ζ CAR T, or CNCT19) in treating 20 pediatric and adult patients with R/R B-ALL.